This suggests that passive immunization with tau antibodies is actually a feasible therapeutic target and that the CSF degree of p-tau262/356 or of the microtubule binding area (MTBD) can function a handy biomarker of tau pathology to monitor tau therapeutics in scientific trials.Initial, they tested this technique on 18 established biosensor lines